Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections
Stockholm, September 25, 2023: Biosergen AB (Biosergen) and Alkem Laboratories Ltd. (Alkem) are pleased to announce the signing of a co-development and license agreement for BSG005, an innovative polyene macrolide, through phase II and phase III trials for sale in the Indian market.Biosergen is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases. After the successful completion of two phase I studies, the first patient trial will be conducted in India on patients with severe fungus disease, who are intolerant or resistant to treatment with